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NOTCH2 Mutations Cause Alagille Syndrome, a Heterogeneous
Disorder of the Notch Signaling Pathway
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David A. Piccoli, and Nancy B. Spinner
Alagille syndrome (AGS) is caused by mutations in the gene for the Notch signaling pathway ligand Jagged1 (JAG1),
which are found in 94% of patients. To identify the cause of disease in patients without JAG1 mutations, we screened
11 JAG1 mutation-negative probands with AGS for alterations in the gene for the Notch2 receptor (NOTCH2). We found
NOTCH2 mutations segregating in two families and identified five affected individuals. Renal manifestations, a minor
feature in AGS, were present in all the affected individuals. This demonstrates that AGS is a heterogeneous disorder and
implicates NOTCH2 mutations in human disease.
From the Divisions of Human Genetics and Molecular Biology (R.M.; D.M.W.; P.A.S.-L.; A.P.; I.D.K.; N.B.S.) and Gastroenterology and Nutrition (D.A.P.),
Department of Pediatrics, and Department of Pathology and Laboratory Medicine (N.B.S.), The Children’s Hospital of Philadelphia and University of
Pennsylvania School of Medicine, Philadelphia
Received February 14, 2006; accepted for publication April 10, 2006; electronically published May 10, 2006.
Address for correspondence and reprints: Dr. Nancy B. Spinner, Division of Human Genetics and Molecular Biology, 1007A Abramson Research Center,
3615 Civic Center Boulevard, The Children’s Hospital of Philadelphia, Philadelphia, PA 19104. E-mail: spinner@mail.med.upenn.edu
Am. J. Hum. Genet. 2006;79:169–173.  2006 by The American Society of Human Genetics. All rights reserved. 0002-9297/2006/7901-0020$15.00
Alagille syndrome (AGS [MIM 118450]) is a dominant,
multisystem disorder defined clinically by hepatic bile
duct paucity and cholestasis in association with cardiac,
skeletal, and ophthalmologic manifestations. There are
characteristic facial features and less-frequent clinical in-
volvement of the renal and vascular systems.1,2 Expressiv-
ity is known to be highly variable. AGS is caused by mu-
tations in the gene encoding Jagged1 (JAG1), a ligand in
the Notch signaling pathway.3,4 Notch signaling is in-
volved in cell fate determination and is essential for nor-
mal embryonic development. At least five ligands and four
Notch receptors are expressed in humans, and many genes
have been identified that function downstream of Notch.5
Mutations in JAG1 were identified in 94% of individuals
with a clinically confirmed diagnosis of AGS.6 Failure to
identify mutations in the remaining patients could have
been because the mutations were located in noncoding
regions not screened by present techniques or were in
another gene. Data from the mouse have implicated the
Notch2 gene in the etiology of clinical features associated
with AGS. Although the Jagged1 knockout heterozygote
mouse did not mimic the AGS phenotype,7 a Jagged1/
Notch2 double heterozygote was found to have liver, car-
diac, ocular, and renal manifestations similar to those seen
in patients with AGS.8 Additionally, the spatial and tem-
poral expression pattern of Notch2 in tissues involved in
AGS makes it an excellent candidate to be the receptor
interacting with Jagged1.9,10 This led us to screen a cohort
of JAG1 mutation-negative patients with AGS for altera-
tions in NOTCH2.
Eleven probands were screened for the coding region
(34 exons) of NOTCH2. All individuals were enrolled in
an institutional review board–approved protocol at The
Children’s Hospital of Philadelphia, after informed con-
sent was obtained. Screening was accomplished by direct
sequencing of purified genomic DNA after PCR amplifi-
cation. The first four exons of NOTCH2 (located within
chromosome band 1p12) have a high degree of homology
with a distinct but related gene, N2N, which is located at
1q21.11 We therefore designed primers for the first four
exons of NOTCH2 so that the 3′ end sat on a nucleotide
unique to NOTCH2, to avoid amplification of N2N. Prim-
ers are listed in table 1.
Mutations were identified in two probands. Proband 1
had cholestatic liver disease, cardiac disease (peripheral
pulmonic stenosis and a small atrial septal defect), char-
acteristic facial features, and severe infantile renal disease
(small kidneys with cysts bilaterally, renal tubular acidosis,
and renal insufficiency) (fig. 1a). He died of cardiopul-
monary arrest at age 2 years. His mother had valvular and
peripheral pulmonic stenosis, characteristic facial features,
and dysplastic kidneys and proteinuria that resulted in
renal failure and a kidney transplant. A NOTCH2 mutation
of the splice acceptor of exon 33 (c.59301GrA) was iden-
tified in the proband and his mother (fig. 1b). Maternal
grandparents and three of the mother’s siblings were also
tested, and they did not carry the mutation, indicating it
was a de novo change in the proband’s mother.
To determine the effect of this mutation on splicing, we
analyzed cDNA prepared from a lymphoblastoid cell line
from the proband. Gel electrophoresis of an amplified por-
tion of the proband’s NOTCH2 cDNA encompassing exons
32–34 confirmed the presence of an abnormal band,
which, by sequencing, was shown to have the 98-bp exon
33 spliced out (fig. 1c). The transcript resulting from this
mutation is predicted to have a premature termination
codon within exon 34, and, since this is the last exon, the
transcript is not predicted to undergo nonsense-mediated
mRNA decay.12 The resulting protein is predicted to lack
three of the seven ankyrin repeats and the ensuing 3′ se-
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Table 1. NOTCH2 Mutation-Screening Primers
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 1. NOTCH2 mutation in family 1. a, Proband and his mother demonstrate features of AGS. Family members marked with an
asterisk (*) were tested for the presence of the mutation but had only wild-type sequence. Individuals marked with a section symbol
(§) had mutant sequences. b, Genomic DNA (gDNA) and cDNA sequencing demonstrates the presence and consequences of a mutation
in the splice site of exon 33 in the proband and his mother. c, cDNA amplification and electrophoresis demonstrate the abnormally
spliced product (arrow). d, Predicted protein product is represented below the diagram of the wild-type Notch2 protein (mutation marked
by an asterisk). EGFR p EGF-like repeats.
quence. (fig. 1d). The ankyrin repeat is found in a num-
ber of proteins and is responsible for mediating protein-
protein interactions.13 These repeats in the intracellular
domain of the Notch proteins interact with nuclear co-
factors that serve to modulate Notch signaling, and the
ankyrin repeats have been shown to be crucial for Notch
activity.14
Proband 2 had cholestatic liver disease, which led to a
liver transplant. She had cardiac disease (tetralogy of
Fallot) and ocular findings (posterior embryotoxon). She
demonstrated renal disease (tubular acidosis and dysplas-
tic kidneys), and currently, at age 8 years, she is awaiting
a renal transplant. Her mother has a history of asymp-
tomatic hematuria and proteinuria. She came to medical
attention at age 26 years with a mildly elevated urine pro-
tein level (155 mg/24 hr), which increased steadily over
the next 10 years (584 mg/24 hr at age 36 years). Hyper-
tension was diagnosed when she was age 36 years. Ab-
dominal ultrasound indicated normal renal sizes. No car-
diovascular or gastrointestinal abnormalities were present.
The diagnosis was subnephrotic-range proteinuria with
microscopic hematuria and no evidence of renal insuffi-
ciency. Examination by a dysmorphologist revealed the
presence of facial features characteristic of AGS (fig. 2a).
The proband’s maternal grandmother has advanced
chronic renal insufficiency of undetermined etiology,
which was first noted at age 59 years. Her renal insuffi-
ciency worsened until age 65 years, when she began peri-
toneal dialysis. An ultrasound of the kidneys showed a
right atrophic kidney, which was thought to be congen-
ital. Cardiac evaluation was negative for a murmur, and
there was no history of liver disease. Adult-onset diabetes
was diagnosed just before dialysis was begun, but this con-
dition is well controlled with diet alone.
Screening of the NOTCH2 gene in the proband, her
mother, and her grandmother identified a GrA change at
position 1331 in the cDNA sequence (c.1331GrA) in exon
8, which causes a substitution of a tyrosine for a cysteine
residue in the 11th epidermal growth factor (EGF)–like
repeat (C444Y) (fig. 2b and 2c). The EGF-like repeat motif
consists of six cysteine residues, forming three intramo-
lecular disulfide bridges, which are crucial for conforma-
tional stability of the protein.15 Loss or gain of cysteine
residues in the EGF-like repeats of other genes has been
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Table 2. Polymorphisms Identified in NOTCH2
Nucleotide
Changea
Exon or
Intron (IVS)
Amino
Acid Frequencyb
c.214CrG Exon 1 7/138
c.15CrT Exon 1 Arg5 16/138
c.87410GrA IVS 6 3/138
c.939CrT Exon 6 Gly507 2/138
c.1396CrA Exon 8 Glu466Lys 1/358
c.1681142ArC IVS 11 1/138
c.191589CrT IVS 12 5/138
c.1915201GrC IVS 12 6/138
c.236539TrG IVS 15 17/138
c.236547TrA IVS 15 18/138
c.247920GrC IVS 16 46/138
c.275344CrT IVS 18 20/138
c.3034TrC Exon 19 Leu1012 1/138
c.318476GrA IVS 20 19/138
c.352358GrA IVS 22 25/138
c.365596GrT IVS 23 26/138
c.365622GrA IVS 23 20/138
c.3980ArG Exon 24 Asp1327Gly 3/358
c.400545ArG IVS 25 16/138
c.4005232CrG IVS 25 1/138
c.4014CrT Exon 25 Ser1338 2/138
c.4305GrA Exon 25 Arg1435 3/138
c.485954GrC IVS 27 1/138
c.4859152CrT IVS 27 20/138
c.4859191GrA IVS 27 3/138
c.5103ArG Exon 28 Lys1701 1/138
c.5310171GrA IVS 30 24/138
c.5310195TrG IVS 30 3/138
c.6028116CrT IVS 34 12/138
c.602884GrT IVS 34 2/138
c.6224GrA Exon 34 Val2075Met 2/358
c.6421CrT Exon 34 Leu2141 2/138
c.7341TrA Exon 34 Gly2447 20/138
a Numbering is based on NOTCH2 cDNA sequence (GenBank
accession number NM_024408.2).
b Frequency is presented as number of occurrences per num-
ber of chromosomes sequenced and refers to both patients
and controls.
Figure 2. NOTCH2 mutation in family 2. a, Proband, her mother, and her grandmother had clinical features associated with AGS. The
family member marked with an asterisk (*) was tested for the presence of the mutation but had only wild-type sequence. Individuals
marked with a section symbol (§) had mutant sequences. b, Sequence analysis shows a mutation in exon 8 in all three affected individuals.
c, The mutation (asterisk) is predicted to cause substitution of a tyrosine for a cysteine residue in EGF-like repeat 11 of Notch2.
shown to cause disease. Examples include loss or gain of
EGF-like cysteine residues in fibrillin, which results in Mar-
fan syndrome,16 and Notch3, which results in cerebral au-
tosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy (CADASIL).17 The Drosophila
and mammalian Notch genes are highly conserved, and
both contain 36 EGF-like repeats, with EGF repeats 11 and
12 required for ligand binding of the Drosophila Notch,
providing further support for the significance of the ob-
served mutation.18
Neither of the mutations we identified was found in 110
ethnically matched control individuals (220 chromo-
somes). These studies identified a number of polymor-
phisms in NOTCH2, which are listed in table 2.
Data presented here indicate that AGS is a genetically
heterogeneous disorder caused by mutations in the Notch
signaling pathway ligand gene, JAG1, or the gene for its
receptor, NOTCH2. However, at this time, the vast major-
ity of patients with AGS have mutations in the JAG1 gene,
with only a small subset showing NOTCH2 mutations.
This may be a matter of ascertainment bias, in that more
patients with NOTCH2 mutations may be found who do
not meet the full criteria we used to select patients with
AGS. It is also possible that a single NOTCH2 mutation
does not, by itself, cause AGS, but perhaps there are poly-
morphisms in JAG1 or other Notch signaling pathway
genes that are necessary to cause the phenotype. We an-
alyzed the complete JAG1 gene in the two probands with
NOTCH2 mutations, and both had multiple JAG1 poly-
morphisms, although all of these were common and did
not result in an amino acid alteration. Further work is
needed to understand why NOTCH2 mutations are rela-
tively rare in the AGS population.
To our knowledge, this is the first report of mutations
in the NOTCH2 gene causing human disease. Germline
mutations in two other Notch receptor genes have been
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associated with human disease: congenital cardiac disease,
in patients with NOTCH1 mutations,19 and CADASIL, in
patients with NOTCH3 mutations.17 Both probands we
identified with NOTCH2 mutations clearly meet the di-
agnostic criteria for AGS, which require the presence of
three of five clinical features (cholestasis, cardiac disease,
ocular abnormality, skeletal abnormality, and character-
istic facial features). It is of interest that the renal disease
in both probands was severe. In addition, renal disease
was present in all three mildly affected relatives who also
carried the NOTCH2 mutation. Renal disease has been re-
ported in 40%–70% of patients with a clinical diagnosis
of AGS.1,2 Renal tubular acidosis and small kidneys are the
most common findings, although severe renal pheno-
types, including renal failure, have been described.20 Mi-
croscopic examination of the kidneys of 26 children with
AGS revealed glomerular lesions of varying severity in 18
children and mild changes in the remaining 8 children.21
In our cohort, there were 59 JAG1 mutation-positive par-
ents. Of the 59, 3 had renal anomalies. These included
two parents with renal failure (one complicated by the
presence of diabetes) and one parent with a deformity of
the left ureter. There is evidence from mouse studies that
functional Notch2 is required for normal kidney devel-
opment, because mice homozygous for a hypomorphic
Notch2 mutation died perinatally secondary to defects in
glomerular development.22 This work raises the possibility
that AGS caused by mutations in NOTCH2 will be found
to have a phenotypic profile different from that of AGS
caused by mutations in JAG1.
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